Skip to content

Statin Intensification and LDL Cholesterol Reduction are Associated with Longitudinal Changes in Circulating Amyloid-β 1–40 in a Prospective Dyslipidemia Cohort

Apr 2026 · Thrombosis and Haemostasis · 0 citations · 52 references
Medicine

TL;DR

In high-risk patients, statin initiation or intensification is associated with a short-term increase, followed by a long-term return to initial Aβ40 circulating levels, whereas patients achieving LDL-C reduction show long-term stabilization of Aβ40 levels.

Abstract

Background Circulating amyloid β 1–40 (Aβ40), a pro-inflammatory and pro-atherogenic peptide, is an emerging biomarker in atherosclerotic cardiovascular disease (ASCVD), but evidence on its modulation by cardiovascular therapies is limited and conflicting. We explored associations between statin therapy and Aβ40 plasma levels. Methods In this prospective study, patients with dyslipidemia ( n  = 146) were consecutively recruited. Αβ40 was measured in plasma by enzyme-linked immunosorbent assay at baseline, after a mean follow-up of 5.2 (visit 2 [V2]) and 15 months (visit 3 [V3]). Patients in whom statin treatment was initiated or intensified ( n  = 68, intensification group) were compared with patients who were untreated or on stable statin intensity ( n  = 78, control group). Results After multivariable adjustment for biologically plausible confounders, increased Aβ40 at baseline associated with ASCVD, heart failure, decreased estimated glomerular filtration rate (eGFR), and diabetes mellitus (DM). Aβ40 increased from baseline to V2 in the intensification group ( p  = 0.05 and adjusted p for interaction = 0.031 vs. the control group) and then stabilized. In the control group, Aβ40 increased at V3 compared with V2 ( p  = 0.043). Excluding ezetimibe-treated patients did not alter these findings. In patients with low-density lipoprotein cholesterol (LDL-C) reduction ≥ 50% at V3, Aβ40 levels remained unchanged, whereas they increased in the rest of the population (adjusted p for group interaction = 0.030). Conclusion In high-risk patients, statin initiation or intensification is associated with a short-term increase, followed by a long-term return to initial Aβ40 circulating levels, whereas patients achieving LDL-C reduction show long-term stabilization of Aβ40 levels. Further research is warranted to clarify the mechanistic insights of these observations.

View source

Similar papers

Open access Sep 2026

Predicting LDL-cholesterol reduction variability on statin-ezetimibe therapy: insights from "Jena auf Ziel".

Upfront dual therapy with atorvastatin (80 mg) and ezetimibe (10 mg) achieved robust LDL‑C reduction with low interindividual variability in treatment-naive individuals, which supports current guideline recommendations for immediate combination therapy in very high-risk patients, irrespective of their baseline metaboli...

U. Makhmudova, D. Lütjohann, F. Haertel et al. · 0 citations
Open access Aug 2026

LDL-C–stratified residual lipoprotein(a) and inflammatory risk after acute myocardial infarction among patients with prior statin use

In patients with AMI despite documented prior statin exposure, the prognostic associations of residual inflammatory and Lp(a) risk appeared to differ across admission LDL-C strata, supporting the potential value of LDL-C–stratified residual risk assessment.

Tian-Shu Gu, Yu-Xin Zhang, Li-Han Zhu et al. · 0 citations
Open access Aug 2026

Event-Driven Intensification and Persistent Therapeutic Inertia in LDL-C Management Among 1,033,703 Patients With ASCVD

In ASCVD patients, LDL-C levels plateau well above guideline targets following an initial decline, and proactive, system-level monitoring and timely intervention are urgently needed to reduce cumulative above-goal LDL-C exposure.

S. Shoji, P. Shrader, Nikki L. B. Freeman et al. · 0 citations
Open access Aug 2026

Association between serum total cholesterol levels and the risk of incident heart failure in patients with atherosclerotic cardiovascular disease

Objective To investigate the association between baseline total cholesterol (TC) levels and incident heart failure (HF) risk in patients with atherosclerotic cardiovascular disease (ASCVD). Methods This retrospective cohort analysis was based on the Kailuan Study, a prospective cohort initiated in Tangshan, China. A to...

Xiao-Xiao Wang, Shou-Lin Wu, Hai-Bo Gao et al. · 0 citations
Aug 2026

Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD.

Long-term fibrate use (compared to statin use) was associated with slower eGFR decline, suggesting renoprotective effects of fibrates, and further studies are warranted to investigate whether fibrate use is beneficial for preventing other outcomes, such as adverse cardiovascular events.

Mohammad Abdullah Al Zubair Naim, Fridtjof Thomas, E. Streja et al. · 0 citations
Open access Aug 2026

The Complex Interplay Between Dyslipidemic Subjects Living with Type 2 Diabetes and Metabolic Syndrome and Statin Treatment: A Reflection on Adherence and Persistence in the Real World

High levels of blood cholesterol are a major risk factor for atherosclerotic cardiovascular disease and require early and consistent utilization of statins as first-line medications to avoid disabling or even deadly consequences. Nevertheless, real-world treatment adherence is significantly lower than that reported in...

F. Strollo, G. Guarino, Ersilia Satta et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.